Latest News

Another myeloma drug with same target as CAR-Ts shows successful Phase II results

Without providing details, GlaxoSmithKline said its trial of BCMA-targeting belantamab mafodotin was positive. The company plans to submit for regulatory approvals later this year – potentially ahead of bluebird and Celgene’s expected filing next year for the CAR-T bb2121.

Source link

Related posts

Patient Safety Movement Foundation nomeia novo presidente do conselho e anuncia determinação para atingir a meta de reduzir a zero as mortes evitáveis de pacientes até 2030

Newsemia

Measuring health-related quality of life in pediatric kidney transplant recipients

Newsemia

STAT Plus: AstraZeneca and GSK drugs reduce risk of ovarian cancer returning, studies find

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World